Abstract:Objective: To investigate the relationship between 1p/16q loss of heterozygosity (LOH) and 1p gain in Wilms tumor and their clinicopathologic characteristics and prognosis. Methods: A total of 175 Wilms tumor samples received from the Department of Pathology, Beijing Children's Hospital from September 2019 to August 2022 were retrospectively analyzed. The histopathologic type and presence of lymph node involvement were evaluated by two pathologists. The clinical data including patients'gender, age, tumor location, preoperative chemotherapy, and tumor stage were summarized. Fluorescence in situ hybridization (FISH) was done to detect 1p/16q LOH and 1p gain and their correlation with the clinicopathological features and prognosis were analyzed. Results: Among the 175 samples, 86 cases (49.1%) were male and 89 (50.9%) were female. The mean age was (3.5±2.9) years, and the median age was 2.6 years. There were 26 (14.9%) cases with 1p LOH, 28 (16.0%) cases with 16q LOH, 10 (5.7%) cases of LOH at both 1p and 16q, and 53 (30.3%) cases with 1q gain. 1q gain was significantly associated with 1p LOH (P<0.01) and 16q LOH (P<0.01). There were significant differences (P<0.01) between 1q gain, 1p LOH and 16q LOH among different age groups. The rate of 16q LOH in the high-risk histopathological subtype (50.0%) was significantly higher than that in the intermediate-risk subtype (13.6%, P<0.05). The frequency of 1q gain, 1p LOH, and 16q LOH in children with advanced clinical stages (Ⅲ and Ⅳ) was significantly higher than that in children with early clinical stages (Ⅰ and Ⅱ). 1q gain, 1p LOH, and 16q LOH showed no significant correlation with gender, unilateral or bilateral disease, chemotherapy, or lymph node metastasis. The progression-free survival (PFS) time for patients with 1q gain and 1p LOH was significantly shorter than those without these aberrations (P<0.05). Additionally, the PFS time of patients with 16q LOH was slightly shorter than those with normal 16q, although the difference was not statistically significant. Patients with stage Ⅲ to Ⅳ disease exhibiting 1q gain or 1p LOH had a significantly higher relative risk of recurrence, metastasis, and mortality. Conclusions: 1p/16q LOH and 1q gain are associated with age, high-risk histological type, and clinical stage in Wilms tumor. 1q gain and 1p LOH are significantly correlated with the prognosis of Wilms tumor.

The Relationship of Expression of Gene P16 and P53 with Biological Behavior and Prognosis of Wilms Tumor

The relationship of expression of p53,p21,Ki-67 and VEGF and bladder cancer stage,grade and prognosis

The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour.

Relations Between Mutation of P_(53) Gene and Histology in Wilms' Tumour

Expression of Proliferating Cell Nuclear Antigen in Wiims'Tumor

The Expression of p16 and p53 Tumor Suppressor Gene in Bladder Carcinoma

Expression of ULBP2 in Wilms' tumor and its prognostic significance

Expression of p53, nm23, p16 tumor suppressor genes in childhood germ cell tumor

The Expression of P16 and P53 Protein and Their Significance in Breast Carcinoma

[Expression and Clinical Significance of P53 Protein and P21(waf1) in Non-Small-cell Lung Carcinoma].

Research Progress on the Relationship among Wilms' Tumor-1 Gene and Its Coding Proteins and Tumor

Expressions and clinical significances of PTEN and P53 gene in non-muscle-invasive bladder cancer

Correlations between Histological and Array Comparative Genomic Hybridization Characterizations of Wilms Tumor

Microdissecting the Genetic Events in the Study of Nephrogenic Rests and Wilms' Tumor Development

The diagnosis and treatment of Wilms' tumor-a review of 69 cases

Identification of key carcinogenic genes in Wilms' tumor

[Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor]

The association of miR-204 and mir-483 5p expression with clinicopathological features of Wilms tumor: Could this provide foresight?

The Abnormality of P16 Gene and the Expression of P16 Protein in Primary Renal Cell Carcinoma

Genetic variation frequencies in Wilms' tumor: A meta‐analysis and systematic review

HnRNPL Promotes Wilms Tumor Progression by Regulating the P53 and Bcl2 Pathways.